Supplementary Information

1,3-Diarylpyrazolyl-acylsulfonamides target HadAB/BC complex in *Mycobacterium tuberculosis*

Vinayak Singh, a,b Anna E. Grzegorzewicz, c Stephen Fienberg, a Rudolf Müller, a Lutete Peguy Khonde, a Olalla Sanz, d Salvatore Alfonso, d Beatriz Urones, d Gerard Drewes, e Marcus Bantscheff, e Sonja Ghidelli-Disse, e Thomas R. Ioerger, f Bhanupriya Angala, c Jiuyu Liu, g Richard E. Lee, g James C. Sacchettini, h Inna V. Krieger, *a,b Mary Jackson, *c Kelly Chibale, *a,b Sandeep R. Ghorpade *a*

a Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa; b South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa; c Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523-1682, USA; d Global Health Pharma Research Unit, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760, Madrid, Spain; e Cellzome GmbH · A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany; f Department of Computer Science and Engineering, Texas A&M University, College Station 77843 Texas, United States; g Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; b Texas A&M University, Department of Biochemistry and Biophysics, ILSB 2138, 301 Old Main Dr, College Station, TX 77843-3474, USA;

*Corresponding Authors

E-mail: kargin@gmail.com; Mary.Jackson@colostate.edu; Kelly.Chibale@uct.ac.za; Sandeep.Ghorpade@uct.ac.za

51
## Contents:

**Methods.** ESKAPE Antimicrobial Screening

**Table S1.** Profiling of selected compounds against ESKAPE pathogens.

**Table S2.** Phenotypic and genotypic profiling of compound 1-resistant mutants

**Table S3.** Structures of compounds utilized to perform chemoproteomics profiling experiments

**Figure S1.** Chemoproteomic profiling using 3-bead-matrix

**Figure S2.** Scatter plot of HadAB pIC\textsubscript{50} vs Mtb pMIC

**Table S4.** 1,3-diarylpyrazolyl-acylsulfonamides against Mtb H37Rv mc\textsuperscript{2}6206 WT and overexpressing hadABC strains.

**Table S5.** Crystallography Data collection and refinement statistics, pdb ID

**Chemistry.** Synthesis and analytical data for compounds 3, 4, 6, 7, 13 and 15

**Figure S3.** Ligand Density map of the bound inhibitor 9 in Complex with Mtb HadAB

**Figure S4.** A 3D illustration of the binding modes of butein and fisetin in the HadAB complex - PDB ID: 4RLW and 4RLT respectively

**Figure S5.** The unliganded structure of the MtbHadBC superimposed onto the crystal structure of MtbHadAB in complex with 9 (turquoise).

**References**
Methods: ESKAPE Antimicrobial Screening

The selectivity of compounds was assessed in a microdilution broth method against the selected Gram negative and one Gram positive strains, in accordance with the Clinical and Laboratory Standards Institute guidelines (CLSI, 2017). The bacterial strains used in this assay included *Escherichia coli* ATCC 25922, *Acinetobacter baumannii* ATCC 19606, *Staphylococcus aureus* ATCC 25923, *Pseudomonas aeruginosa* ATCC 27853, and *Klebsiella pneumoniae* ATCC BAA-1705, and *Enterobacter cloacae* ATCC 700323. Overnight cultures of the different bacterial strains were grown on Müller-Hinton (MH) agar plates at 37°C. Inoculum cultures were prepared in phosphate buffer saline (PBS) to a 0.5 McFarland (OD600 = 0.08) and diluted in MH broth to yield a bacterial concentration of approximately $1.5 \times 10^6$ cfu/mL. The compounds were tested at a concentration range between 0.25 – 128 µM. Furthermore, three antibiotics (ciprofloxacin, gentamycin, moxifloxacin, and kanamycin) were used as controls. Untreated bacterial controls as well as media sterility controls were included in the assay. The prepared plates were incubated at 37°C for 16 hours, followed by a visual assessment. The minimum inhibitory concentration (MIC) values were determined as the lowest concentration where no bacterial growth could be observed.

Table S1. Profiling of selected compounds against ESKAPE pathogens.

| Compound | *Escherichia coli* (ATCC 25922) | *Staphylococcus aureus* (ATCC 25923) | *Klebsiella pneumoniae* (ATCC BAA-1705) | *Acinetobacter baumannii* (ATCC 19606) | *Pseudomonas aeruginosa* (ATCC 27853) | *Enterobacter cloacae* (ATCC 700323) |
|----------|--------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| 1        | >128                           | >128                                | >128                                | >128                                | >128                                | >128                                |
| 2        | >128                           | 128                                 | >128                                | >128                                | >128                                | >128                                |
| 11       | >128                           | >128                                | >128                                | >128                                | >128                                | >128                                |
| 14       | 128                            | >128                                | >128                                | >128                                | >128                                | >128                                |
| Ciprofloxacin | 0.06                      | 0.5                                 | >32                                 | 1                                   | 0.125                               | 0.06                                |
| Gentamycin        | 2                             | 0.5                                 | 4                                   | 16                                  | 2                                   | 2                                   |
| Moxifloxacin     | 0.06                          | 0.06                                | >32                                 | 0.5                                 | 2                                   | 0.06                                |
| Kanamycin       | 4                             | 2                                   | >32                                 | 16                                  | >32                                 | 8                                   |
Table S2. Phenotypic and genotypic profiling of compound 1-resistant mutants

| Strain      | Compound 1 MIC (µM) | Mutation                                      | Comment                                      |
|-------------|---------------------|-----------------------------------------------|----------------------------------------------|
| H37RvMA     | 1.9                 | -                                             | WT reference strain                          |
| SRM59-1     | 50-100              | Rv0637/hadC:K157R Rv2932/ppsB:T1300N           | Both hadC and ppsB are in vitro non-essential genes. |
| SRM59-2     | 50-100              | Rv0637/hadC:K157R Rv2932/ppsB:T1300N           |                                              |
| SRM59-3     | 50-100              | Rv0637/hadC:K157R Rv2932/ppsB:T1300N           |                                              |
Table S3. Compound names and structures utilized to perform chemoproteomic profiling experiments.

| Compound | Structure | Mtb pMIC99 |
|----------|-----------|------------|
| 1        | ![Structure Image] | 6.2        |
| 2        | ![Structure Image] | 5.5        |
| 3        | ![Structure Image] | 6          |
| 4        | ![Structure Image] | 5.4        |
| 5        | ![Structure Image] | 5.6        |
| 6        | ![Structure Image] | <4.3       |
| 7        | ![Structure Image] | <4.3       |
| 8        | ![Structure Image] | <4.3       |

*Mtb* pMIC defined as $-\log_{10}(\text{MIC}_{99} \text{ in M})$
Figure S1. Chemoproteomic profiling using 3-bead-matrix

Chemoproteomic profiling showed only a weak effect on HadC by 1,3-Diarylpyrazolyl-acylsulfonamide series compounds. Correlation of target binding and anti-mycobacterial activity for compounds from the 1,3-Diarylpyrazolyl-acylsulfonamide series. Experiments were performed as described in Fig 1. 5 compounds from the series with activity against Mtb and 3 that did not show activity (see table) were analyzed at 10 µM in two independent replicates on 3-bead-matrix. Active compounds showed inhibition of proteins HadA, HadB, BCG_0547c (HadD) and HadC from 3-bead-binding, while inactive compounds did not show any. HadA/B/D inhibition from bead-binding is in the range of 94-100%, while for HadC the inhibition is in a range of 52-64%, which indicates weaker potential IC50-values for HadC. r: Pearson correlation coefficient; p: p-value (calculated probability), Mtb pMIC defined as -log10(MIC90 in M).
Figure S2. Scatter plot of HadAB pIC$_{50}$ [defined as -log$_{10}$(HadAB IC$_{50}$ in Molar units)] vs $Mtb$ pMIC [defined as -log$_{10}$(MIC in M)]
Table S4. 1,3-diarylpyrazolyl-acylsulfonamides against \textit{Mtb} H37Rv mc\textsuperscript{2}6206 WT and overexpressing \textit{hadABC} strains.

| Compound | \textit{Mtb} WT | \textit{Mtb}/pNIP40b-\textit{hadABC} |
|----------|----------------|-------------------------------------|
| 2        | <0.625         | 2.5                                 |
| 3        | 5              | 20                                  |
| 10       | 1.5            | 3                                   |
| 11       | 0.625          | >40                                 |
| 12       | 3.125          | 12.5                                |
| 13       | 3.75           | 1.9                                 |
| 14       | <0.243         | 15                                  |
| 15       | 3.9            | 7.8                                 |

MICs were determined in 96-well microtiter plates in Middlebrook 7H9 broth supplemented with 0.4% glucose, 0.2% casamino acids, 48 \(\mu\)g/mL pantothenate, 50 \(\mu\)g/mL L-leucine, 0.08% sodium chloride and 0.05% tyloxapol using resazurin blue test (REMA). MICs are expressed in \(\mu\)M.
Table S5. Crystallography Data collection and refinement statistics, pdb ID 7SVT

| Data collection |          |
|-----------------|----------|
| Space group     | P2_12_1 |
| Cell dimensions |          |
| \(a, b, c\) (Å) | 85.3, 107.2, 142.07 |
| \(\alpha, \beta, \gamma\) (°) | 90.00, 90.00, 90.00 |
| Resolution (Å)  | 48.6 – 2.4 (2.47 - 2.4) |
| \(R_{sym}\) or \(R_{merge}\) | 0.198 (1.962) |
| \(I/\sigma I\)  | 7.5 (1.2) |
| Completeness (%)| 99.9 (100) |
| Redundancy      | 5.8 (6) |
| CC1/2           | 0.994 (0.536) |

| Refinement      |          |
|-----------------|----------|
| Resolution (Å)  | 45.38 – 2.4 |
| No. reflections | 51470    |
| \(R_{work}/ R_{free}\) | 0.2173 / 0.2751 |
| No. atoms       |          |
| Protein         | 8976     |
| Ligand/ion(s)   | 140      |
| Water           | 88       |
| B-factors       |          |
| Protein         | 52       |
| Ligand/ion(s)   | 46.8     |
| R.m.s deviations|          |
| Bond lengths (Å)| 0.01     |
| Bond angles (°) | 1.232    |

*Highest resolution shell is shown in parenthesis.
**Chemistry**

Unless otherwise stated, the starting materials, reagents and solvents were purchased as high-grade commercial products. Analytical TLC was performed on Merck silica gel (60F254) precoated plates (0.25 mm). The compounds were visualized under UV light (254 nm) and/or stained with the relevant reagent. Flash column chromatography was performed on silica gel with pore size 60 Å, 230–400 mesh particle size, and 40–63 μm particle size, with the indicated solvents. The yields refer to the purified products, and they were not optimized. All the solid compounds were obtained as amorphous solids, and melting points were not measured. $^1$H NMR spectra were recorded on a Bruker Avance III NMR spectrometer and in a Bruker DPX Avance 400 MHz instrument equipped with a QNP probe and are reported in ppm using tetramethylsilane as internal standard. Mass spectra data measurements were performed on a VG-Analytical Autospec Q mass spectrometer. Analytical purity was ≥95% unless stated otherwise. The purities of the final compounds were determined by using a Waters ZQ2000 coupled with LC Waters 2795 and Waters 2996 PDA detector.

**High-resolution mass method:**

HPLC–HRMS was obtained using an AB Sciex® X500R QTOF coupled to an AB Sciex® Exion LC system. Spectral data were obtained using information dependent acquisition (IDA) at a mass range of 50–1200 Da. All methods, batches and data were processed using OS Sciex® v1.2. The declustering potential was 80 V, the curtain gas ($\text{N}_2$) was at 25 pounds per square inch (psi), the ion spray voltage was 5500 V, and the source temperature was 450°C. Ion source gases 1 and 2 were at 45 and 55 psi, respectively. The collision energy was 10 eV for the MS scans and 20–50 eV for MS/MS scans. The IDA intensity threshold was 50 cycles per second. The aqueous mobile phase used was 1 mM ammonium formate in water, and the organic mobile phase was methanol with 0.5% formic acid. The flow rate was 700 μL/minute, and the method ran from 2% to 98% organic for 25 minutes, was held at 98% organic for a further 2 minutes before returning to 2% organic over 3 minutes to equilibrate for the next run. A Kinetex® C18 LC column (5 μm, 100 Å, 150 mm × 4.6 mm) with a column protector was used. A blank injection was run between each sample. The spectra were processed and displayed using MZMine2.5.
Scheme S1. Synthetic pathway for compounds 3 and 4.

3-(3-(4-bromophenyl)-1-(4-chlorophenyl)-1H-pyrazol-4-yl)-N-(methylsulfonyl) propanamide (17). To a stirring solution of 16 (500 mg, 1.233 mmol) in DMF (5 mL), CDI (400 mg, 2.465 mmol) was added and the solution was stirred at room temperature for 10 min. Methanesulfonamide (141 mg, 1.479 mmol) and DBU (0.223 mL, 1.479 mmol) were added and the reaction mixture stirred overnight at 90 °C. Solvent was removed under reduced pressure and the crude obtained was partitioned between ethyl acetate and NH₄Cl sat. The organic layer was washed with brine, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude obtained was purified by silica gel column chromatography (eluents DCM/MeOH, from 0 to 2% of MeOH), to yield 17 as a yellow solid (32% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 11.73 (s, 1H), 8.42 (s, 1H), 7.92 – 7.84 (m, 2H), 7.68 (s, 4H), 7.61 – 7.54 (m, 2H), 3.20 (s, 3H), 2.96 – 2.87 (m, 2H), 2.62 (t, J = 7.5 Hz, 2H).

Tert-butyl (3-(4-(1-(4-chlorophenyl)-4-(3-(methylsulfonamido)-3-oxopropyl)-1H-pyrazol-3-yl)phenyl)prop-2-yn-1-yl)carbamate (18). Under nitrogen atmosphere, 17 (100 mg, 0.207 mmol), tert-butyl prop-2-yn-1-ylcarbamate (48.2 mg, 0.311 mmol), Palladium(II) acetate (4.65 mg, 0.021 mmol), xantphos (5.99 mg, 10.36 µmol), and cesium carbonate (202 mg, 0.621 mmol) were placed in THF (2.5 mL). The mixture was heated to reflux overnight. The reaction solvent was evaporated under reduced pressure and HCl 2N was added (15 mL). The mixture was extracted with ethyl acetate (20 mL), washed with brine (20 mL), filtered through a celite cartridge and dried over sodium sulphate. The crude product was purified by silica gel column chromatography (DCM:MeOH 99:1; isocratic method). The product fractions were collected and purified again by preparative HPLC (XBridge C18, X_BRIDGE 19x150 60_100 ACID 0.1% TFA in water/ 0.1% TFA in ACN affording 18 as a white solid (12% yield). ¹H NMR (400
3-(3-(4-(3-aminoprop-1-yn-1-yl)phenyl)-1-(4-chlorophenyl)-1H-pyrazol-4-yl)-N-(methylsulfonyl)propenamide (4). To a solution of 18 (34 mg, 0.061 mmol) in 1,4-dioxane (1.526 mL), HCl (4M in 1,4 dioxane) (1.526 mL, 6.10 mmol) was added and the reaction mixture was stirred at rt for 4 h. The reaction mixture was evaporated under reduced pressure. The crude obtained was dissolved in MeOH and evaporated. This process was repeated several times (to remove the excess of acid). The solid obtained was dissolved in MeOH and passed through a SCX (1g cartridge) and after eluting with MeOH three column volumes, desired product was eluted with ammonia in methanol. Solvent was evaporated to yield 4 as pale brown solid (78% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 7.89 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.59 – 7.54 (m, 5H), 3.91 (s, 2H), 2.86 (s, 3H), 2.89 – 2.82 (m, 1H), 2.40 (dd, J = 8.7, 6.9 Hz, 2H). MS-ES⁺ [M+H]⁺ = 457; HPLC purity >95%.

Tert-butyl (3-(4-(1-(4-chlorophenyl)-4-(3-(methylsulfonylamido)-3-oxopropyl)-1H-pyrazol-3-yl)phenyl)propyl)carbamate (19). 18 (56 mg, 0.101 mmol) was dissolved in 40 mL of MeOH/DCM (1:1) and it was hydrogenated in the H-Cube PRO through a catalyst cartridge of palladium on carbon 10% (Pd/C 10% "CatCart") under the following conditions: full H₂, flow: 1 mL/min, temperature: room temperature, pressure: 1 bar and the reaction was passed through the cartridge for 40 min. Solvent was concentrated under reduced pressure and the crude purified by SFC, to yield 2 as white solid (25% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 11.74 (s, 1H), 8.38 (s, 1H), 7.87 (d, J = 9.1 Hz, 2H), 7.62 (d, J = 8.3 Hz, 2H), 7.57 (d, J = 9.1 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 6.88 (br t, J = 5.2 Hz, 1H), 3.21 (s, 3H), 3.01 – 2.86 (m, 4H), 2.66 – 2.57 (m, 4H), 1.71 (quin, J = 7.3 Hz, 2H), 1.38 (s, 9H). MS-ES⁺ [M+H]⁺ = 561

3-(3-(4-(3-aminopropyl)phenyl)-1-(4-chlorophenyl)-1H-pyrazol-4-yl)-N-(methylsulfonyl)propenamide (3). To a solution of 19 (103 mg, 0.184 mmol) in 1,4-dioxane (4.59 mL), was added HCl (4M in 1,4 dioxane) (4.59 mL, 18.36 mmol) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was evaporated under reduced pressure. The crude obtained was dissolved in MeOH and evaporated. This process was repeated several times (to remove the excess of acid). The solid obtained was dissolved in MeOH and passed through a SCX (1g cartridge) and after eluting with MeOH three column volumes, desired product was eluted with ammonia in methanol. Solvent was evaporated to yield 3 as pale brown solid (73% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (s, 1H), 7.87 (d, J = 9.1 Hz, 2H), 7.66 (d, J = 8.1 Hz, 3H), 7.55 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.3 Hz, 2H), 2.84 – 2.76 (m, 4H), 2.74 (s, 3H), 2.70 (t, J = 7.6 Hz, 2H), 2.32 – 2.25 (m, 2H), 1.88 (quin, J = 7.6 Hz, 2H). ¹³C NMR (151 MHz, MeOD) δ 186.1, 160.0, 149.8, 147.9, 140.7, 139.2, 138.8 (2C), 137.9 (2C), 137.0 (2C), 131.2, 128.8 (2C), 49.7, 49.5, 47.9, 41.0, 38.1, 30.5. HRMS: calculated for C₂₂H₂₆ClN₄O₃S [M+H]⁺, 461.1409 found 461.1429. HPLC purity >95%.
$^1$H NMR spectrum of compound 4

$^1$H NMR (400 MHz, DMSO-d$_6$)  δ 8.42 (s, 1H), 7.89 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 6.6 Hz, 2H), 7.59 - 7.54 (m, 5H), 3.91 (s, 2H), 2.86 (s, 3H), 2.89 - 2.82 (m, 1H), 2.40 (dd, J = 8.7, 6.9 Hz, 2H)
LC-MS chromatogram of compound 4

Sample amount: 1 mg
Solvent: DMSO
Concentration: 1 mg/mL
Column: Acquity UPLC BEH C18 1.7u 3x50mm
Method: 0.1% Formic Acid in Water / 0.1% Formic Acid in ACN
Initial: 95:5
0.0 – 1.4 min 0:100
1.4 – 1.9 min 0:100
1.9 – 2.0 min 95:5
Flow: 0.8 mL/min
Inj. Vol.: 0.2 uL
T*: 50°C

| Retention Time (min) | Molecular Formula | Monoisotopic Mass | [M+H]^+ | [M-H]^- | Purity (297nm) |
|----------------------|-------------------|-------------------|---------|---------|----------------|
| 0.91                 | C22H21ClN4O3S     | 456.10            | 457     | >95     |

Chromatograms & Spectra:
$^1$H NMR spectrum of compound 3

$^1$H NMR (400 MHz, DMSO-d$_6$) $\delta$ 3.38 (s, 3H), 3.87 (d, $J$ = 9.1 Hz, 3H), 7.06 (d, $J$ = 8.1 Hz, 2H), 7.55 (d, $J$ = 8.5 Hz, 2H), 7.35 (d, $J$ = 8.3 Hz, 2H), 2.94 - 2.76 (m, 4H), 2.74 (s, 3H), 2.70 (d, $J$ = 7.6 Hz, 2H), 2.32 - 2.25 (m, 3H), 1.88 (s, $J$ = 7.6 Hz, 2H)

$^{13}$C NMR spectrum of compound 3
LC chromatogram of compound 3

Sample amount: 1 mg
Solvent: DMSO
Concentration: 1 mg/mL
Column: Acquity UPLC BEH C18 1.7u 3x50mm
Method: 0.1% Formic Acid in Water / 0.1% Formic Acid in ACN
Initial: 95:5
0.0 – 1.4 min 0:100
1.4 – 1.9 min 0:100
1.9 – 2.0 min 95:5
Flow: 0.8 mL/min
Inj. Vol.: 0.2 uL
T°: 50°C

| Retention Time (min) | Molecular Formula | Monoisotopic Mass | [M+H]⁺ | [M+H]⁻ | Purity (287 nm) |
|----------------------|-------------------|-------------------|--------|--------|----------------|
| 0.91                 | C22H25ClN4O3S     | 460.13            | 461    |        | >95            |

Chromatograms & Spectra:
Synthesis of (E)-3-(1,3-bis(4-chlorophenyl)-1H-pyrazol-4-yl)-2-methyl-N-(methylsulfonyl)acrylamide (6)

Compound 6 was synthesized as described for compound 17 and reported earlier. Compound 6 was isolated as a white crystal. Yield: 19%. $^1$H NMR (300 MHz, DMSO-d$_6$) δ 11.66 (s, 1H), 8.84 (s, 1H), 8.11 – 8.00 (m, 2H), 7.76 – 7.67 (m, 2H), 7.68 – 7.55 (m, 4H), 7.33 (s, 1H), 2.12 (d, $J$ = 1.2 Hz, 3H). $^{13}$C NMR (151 MHz, DMSO-d$_6$) δ 168.3, 151.7, 137.8, 133.5, 131.2, 130.8, 130.2 (2C), 129.5 (2C), 129.3, 129.1, 128.8 (2C), 127.3, 120.6 (2C), 116.4, 41.2, 14.5. HRMS: calculated for C$_{20}$H$_{18}$Cl$_2$N$_3$O$_3$S [M+H]$^+$, 450.0440 found 450.0453. HPLC purity 97%.

$^1$H NMR spectrum of compound 6
$^{13}$C NMR spectrum of compound 6
LC chromatogram of compound 6

| Signal 1: DAD1 E, Sig=288,4 Ref=550,10 |
|----------------------------------------|
| Peak RetTime | Type | Width | Area         | Height | Area |
|--------------|------|-------|--------------|--------|------|
| 1            |      |       | 1.999 0.0026 | 4623.76758 | 3453.33802 | 97.4291 |
| 2            |      |       | 2.882 0.0195 | 54.13139  | 46.39372  | 1.1405 |
| 3            |      |       | 2.126 0.0216 | 30.55798  | 22.87267  | 0.6439 |
| 4            | MH   |       | 2.352 0.0808 | 37.31818  | 36.80465  | 0.7863 |

Sorted By: Signal
Multiplier: 1.0000
Dilution: 1.0000
Use Multiplier & Dilution Factor with ISVDs
Synthesis of 3-(1-(4-bromophenyl)-3-(4-chlorophenyl)-1H-pyrazol-4-yl)-N-(tert-butylsulfonyl)propanamide (7)

Compound 7 was synthesized according to the same synthetic procedure described for compound 6 and 17. Compound 7 was isolated as a white solid. Yield: 22%. 1H NMR (400 MHz, MeOD) δ 8.13 (d, J = 0.8 Hz, 1H), 7.74 – 7.67 (m, 4H), 7.65 – 7.58 (m, 2H), 7.49 – 7.42 (m, 2H), 3.02 (t, J = 7.2 Hz, 2H), 2.65 (t, J = 7.2 Hz, 2H), 1.31 (s, 9H). 13C NMR (151 MHz, MeOD) δ 173.4, 152.0, 140.4, 135.2, 133.6 (2C), 133.3, 130.5 (2C), 129.8 (2C), 129.1, 121.5 (2C), 121.4, 120.5, 62.5, 37.9, 24.5 (3C), 20.7. HRMS: calculated for C_{22}H_{24}BrClN_{3}O_{3}S [M+H]^+, 524.0405 found 524.0413; HPLC purity 97%.

1H NMR spectrum of compound 7
$^{13}$C NMR spectrum of compound 7

LC chromatogram of compound 7
Scheme S2: Synthetic pathway for compound 13.

Synthesis of 2-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)acetohydrazide (21): To a stirred solution of 2-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)acetic acid 20 (3.0 g, 9.56 mmol), tert-butyl carbazate (2.5 g, 19.12 mmol) and diisopropylethyl amine (8.5 mL, 47.81 mmol) in dimethylformamide (25 mL), was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl (2.7 g, 14.34 mmol). The reaction mixture was stirred at room temperature for 16 h. Water was added and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with brine (1 x 50 mL) dried over sodium sulphate and concentrated under vacuum. The crude product was purified by column chromatography using 230-400 mesh silica gel with 30-50% ethyl acetate in petroleum ether to obtain Boc intermediate (2.8 g, 70%). The intermediate was dissolved in 1,4-dioxane (30 mL) and 4N HCl in 1,4-dioxane (10 mL) was added and stirred for 3 h. The solvent was evaporated under vacuum to obtain 21 (1.4 g, 67%). 1H NMR (400 MHz, DMSO-d6): δ 11.56 (s, 1H), 8.93 (d, J = 5.60 Hz, 2H), 8.74 (s, 1H), 8.33 (d, J = 5.20 Hz, 2H), 7.99 (d, J = 5.20 Hz, 2H), 7.64 (d, J = 9.20 Hz, 2H), 3.93 (s, 2H), 3.16 (d, J = 5.20 Hz, 2H), LC-MS APCI: MS-ES+ [M+H]+ = 328.1.

Synthesis of 5-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole-2-thiol (22): 2-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)acetoxydrazine 21 (1.4 g, 4.27 mmol), carbon disulphide (0.52 mL, 8.54 mmol), potassium hydroxide (0.7 g, 12.81 mmol) and ethanol (20 mL) were taken in a sealed tube and heated to 90 °C for 16 h. Ethanol was evaporated under vacuum. The residue was dissolved in 1,4-dioxane (30 mL) and 4N HCl in 1,4-dioxane (10 mL) was added and stirred for 3 h. The solvent was evaporated under vacuum to obtain 21 (1.4 g, 67%). The intermediate was dissolved in 1,4-dioxane (30 mL) and 4N HCl in 1,4-dioxane (10 mL) was added and stirred for 3 h. The solvent was evaporated under vacuum to obtain 21 (1.4 g, 67%). 1H NMR (400 MHz, DMSO-d6): δ 11.56 (s, 1H), 8.93 (d, J = 5.60 Hz, 2H), 8.74 (s, 1H), 8.33 (d, J = 5.20 Hz, 2H), 7.99 (d, J = 5.20 Hz, 2H), 7.64 (d, J = 9.20 Hz, 2H), 3.93 (s, 2H), 3.16 (d, J = 5.20 Hz, 2H), LC-MS APCI: MS-ES+ [M+H]+ = 328.1.

Synthesis of 5-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole-2-thiol (22): 2-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)acetoxydrazine 21 (1.4 g, 4.27 mmol), carbon disulphide (0.52 mL, 8.54 mmol), potassium hydroxide (0.7 g, 12.81 mmol) and ethanol (20 mL) were taken in a sealed tube and heated to 90 °C for 16 h. Ethanol was evaporated under vacuum. The residue was dissolved in 1,4-dioxane (30 mL) and 4N HCl in 1,4-dioxane (10 mL) was added and stirred for 3 h. The solvent was evaporated under vacuum to obtain 21 (1.4 g, 67%). The intermediate was dissolved in 1,4-dioxane (30 mL) and 4N HCl in 1,4-dioxane (10 mL) was added and stirred for 3 h. The solvent was evaporated under vacuum to obtain 21 (1.4 g, 67%). The intermediate was dissolved in 1,4-dioxane (30 mL) and 4N HCl in 1,4-dioxane (10 mL) was added and stirred for 3 h. The solvent was evaporated under vacuum to obtain 21 (1.4 g, 67%). 1H NMR (400 MHz, DMSO-d6): δ 11.56 (s, 1H), 8.93 (d, J = 5.60 Hz, 2H), 8.74 (s, 1H), 8.33 (d, J = 5.20 Hz, 2H), 7.99 (d, J = 5.20 Hz, 2H), 7.64 (d, J = 9.20 Hz, 2H), 3.93 (s, 2H), 3.16 (d, J = 5.20 Hz, 2H), LC-MS APCI: MS-ES+ [M+H]+ = 328.1.

Synthesis of 2-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-5-(methylthio)-1,3,4-oxadiazole (23): To a solution of 5-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole-2-thiol 22 (0.5 g, 1.35 mmol) and potassium acetate (0.26 g, 2.70 mmol) in ethanol (10 mL), was added methyl iodide (0.12 mL, 2.02 mmol) at 0°C. The reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated under vacuum and the residue was taken for column purification using 230-400 mesh silica gel with 1-2% methanol in dichloromethane as eluent to obtain 22 (0.6 g, Crude). MS-ES+ [M+H]+ = 370.0. The crude product was taken as such for next step.

Synthesis of 2-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-5-(methylthio)-1,3,4-oxadiazole (23): To a solution of 5-(1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole-2-thiol 22 (0.5 g, 1.35 mmol) and potassium acetate (0.26 g, 2.70 mmol) in ethanol (10 mL), was added methyl iodide (0.12 mL, 2.02 mmol) at 0°C. The reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated under vacuum and the residue was taken for column purification using 230-400 mesh silica gel with 1-2% methanol in dichloromethane as eluent to obtain 22 (0.6 g, Crude). MS-ES+ [M+H]+ = 370.0. The crude product was taken as such for next step.
$J = 4.64$ Hz, 2H), 8.08 (s, 1H), 7.05-7.73 (m, 4H), 7.48 (d, $J = 6.84$ Hz, 2H), 4.30 (s, 2H), 2.78 (s, 3H). MS-ES$^+$ [M+H]$^+$ = 384.0.

**Synthesis of 2-((1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-5-(methylsulfonyl)-1,3,4-oxadiazole (13):** To a stirred solution of 2-((1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-5-(methylthio)-1,3,4-oxadiazole 23 (0.18 g, 0.46 mmol) in dichloromethane (15 mL) was added m-chloroperbenzoic acid (0.18 g, 1.03 mmol) and stirred for 12 h at room temperature. The reaction mixture was washed with aqueous sodium bicarbonate solution (1 x 10 mL), water (1 x 10 mL), dried over sodium sulphate and concentrated under vacuum. The crude product was purified with preparative HPLC to yield 2-((1-(4-chlorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methyl)-5-(methylsulfonyl)-1,3,4-oxadiazole 13 (15 mg, 8%). $^1$H NMR (400 MHz, MeOD): $\delta$ 8.50 (s, 1H), 8.42 (d, $J = 6.64$ Hz, 2H), 8.03 (d, $J = 6.56$ Hz, 2H), 7.89 (d, $J = 8.56$ Hz, 2H), 7.55 (d, $J = 8.56$ Hz, 2H), 4.62 (s, 2H), 3.21 (s, 3H). $^{13}$C NMR (151 MHz, MeOD) $\delta$ 157.0, 148.2, 145.0, 140.5, 139.6, 135.7, 134.3, 133.8, 132.0, 131.3, 130.8, 130.7, 126.1, 121.8, 121.5, 115.4, 48.7 (overlapped with MeOD), 23.2. HRMS: calculated for C$_{18}$H$_{14}$ClN$_{5}$O$_{3}$S [M+H]$^+$, 416.0579 found 416.0565; HPLC purity 93.8%.

$^1$H NMR spectrum of 13
$^{13}$C NMR spectrum of 13

LC chromatogram of 13
Scheme S3. Synthetic pathway for compound 15.

1-(4-chlorophenyl)pentane-1,3-dione (25): A solution of propionic acid (1.01 mL, 13.50 mmol) and CDI (3.38 g, 20.25 mmol) in anhydrous DMF (10 mL) was allowed to stir at room temperature under N₂ atmosphere for 3 hours. The mixture was added portion wise to a vigorous stirring suspension of 1-(4-chlorophenyl)ethan-1-one (24, 1.751 mL, 13.50 mmol) and sodium hydride 60% suspension in mineral oil (1.620 g, 40.5 mmol) in DMF (10 mL). The resulting reaction mixture was allowed to stir at 80 °C under N₂ atmosphere for 15 hours. The reaction mixture was allowed to cool at room temperature and poured into ice-cold and neutralised with 2 N HCl. The obtained aqueous layer was extracted with EtOAc (4 x 25 mL). The combined organic layers were washed with water, followed by brine, dried over MgSO₄, filtered and solvent evaporated in vacuo to yield a brown residue. The obtained residue was adsorbed into silica gel and purified using an ISCO Teledyne CombiFlash system (40 g SiO₂ cartrige) eluting a gradient of EtOAc in hexane (hexane 100% to hexane/EtOAc 95:5). Pure fractions were combined to yield 25 (0.492 g, 2.195 mmol, 16% yield) a yellow liquid. Intermediate used in the next step without further purification. MS-ES⁺ [M+H]⁺ = 211.0

1,3-bis(4-chlorophenyl)-5-ethyl-1H-pyrazole (27): To a stirring solution of 28 (0.693 g, 3.29 mmol) in methanol (40 mL) was added (4-chlorophenyl)hydrazine, Hydrochloride (0.589 g, 3.29 mmol). The resulting reaction mixture was allowed to reflux at 75 °C for 17 hours. LC-MS revealed clear product formation. The solvent was removed in vacuo to yield a residue which was adsorbed into silica gel and purified using an ISCO Teledyne CombiFlash system (25 g SiO₂ cartrige) eluting a gradient of EtOAc in hexane (hexane 100% to hexane/EtOAc 95:5) to yield two isomers, early fractions afforded the minor isomer 27 (0.236 g, 0.655 mmol, 20 % yield) as a yellow oil and later fractions afforded 1,5-bis(4-chlorophenyl)-3-ethyl-1H-pyrazole (26, 0.378 g, 1.180 mmol, 36 % yield) as a yellow oil. Intermediates used in the next step without further purification.

Data for 27: ¹H NMR (300 MHz, CDCl₃) δ 7.89 – 7.83 (m, 2H), 7.49 (d, J = 2.8 Hz, 4H), 7.41 (d, J = 8.5 Hz, 2H), 6.58 (s, 1H), 2.72 (q, J = 7.5 Hz, 2H), 1.31 (t, J = 7.5 Hz, 3H). MS-ES⁺ [M+H]⁺ = 317.0
**Data for 26:** $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.38 – 7.29 (m, 4H), 7.25 – 7.12 (m, 4H), 6.40 (s, 1H), 2.85 (q, $J = 7.6$ Hz, 2H), 2.13 (t, $J = 7.6$ Hz, 3H). MS-ES$^+$ [M+H]$^+$ = 317.0.

1,3-bis(4-chlorophenyl)-5-ethyl-1H-pyrazole-4-carbaldehyde (28): To a stirring solution of 27 (236 mg, 0.744 mmol) in DMF (15 mL) was added POCl$_3$ (2.08 mL, 22.32 mmol) slowly at ambient temperature and the resulting reaction mixture was heated at 80°C for 19 hours. The reaction mixture was cooled and poured onto ice-water and basified to pH=8 with NaOH. The obtained aqueous layer was extracted with EtOAc and the combined organic layers were washed with H$_2$O (10 mL) followed by brine (10 mL), dried over MgSO$_4$, filtered and solvent evaporated in vacuo to yield 28 (109 mg, 0.316 mmol, 42 % yield) as a yellow solid. Intermediate was used in the next step without further purification.

1,3-bis(4-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl)methanol (29): In an ice-cold water bath, a solution of 28 (109 mg, 0.316 mmol) in methanol (15 mL) was added sodium borohydride (23.89 mg, 0.631 mmol) portion wise and the resulting reaction mixture was allowed to stir at room temperature for 1 hour. The reaction was quenched by careful addition of H$_2$O (10 mL) followed by brine (10 mL), then dried over MgSO$_4$, filtered and solvent evaporated in vacuo to yield a crude product.

(1,3-bis(4-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl)methyl (methylsulfonyl)carbamate (15): A pressure tube containing a solution of N-ethyl-N-isopropylpropan-2-amine (0.310 mL, 1.774 mmol), methanesulfonamide (42.2 mg, 0.443 mmol) and di(1H-imidazol-1-yl)methanone (71.9 mg, 0.443 mmol) in DCM (5 mL) was allowed to stir at room temperature for 16 hours. To this solution was added 28 (77 mg, 0.222 mmol) in DCM (5 mL) and the resulting reaction mixture was allowed to stir at 70°C for 24 hours. At the end, the reaction mixture was cooled to room temperature, diluted with water and extracted with DCM (4 X 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO$_4$, filtered and solvent evaporated in vacuo to afford 15 (30 mg, 0.062 mmol, 28 % yield) as a white solid. $^1$H NMR (300 MHz, MeOD) $\delta$ 7.71 (d, $J = 8.5$ Hz, 2H), 7.60 (d, $J = 8.8$ Hz, 2H), 7.52 (d, $J = 8.8$ Hz, 2H), 7.47 (d, $J = 8.5$ Hz, 2H), 5.23 (s, 2H), 3.21 (s, 3H). $^13$C NMR (151 MHz, MeOD) $\delta$ 186.2, 160.0, 149.8, 147.9, 140.7, 139.2, 138.8 (2C), 137.9 (2C), 137.0 (2C), 136.9, 131.3, 128.8 (2C), 48.0, 41.0, 38.2, 30.6. HRMS: calculated for C$_{20}$H$_{20}$Cl$_2$N$_3$O$_4$S [M+H]$^+$, 468.0546 found 468.0566. : HPLC purity 97%.
$^{1}H$ NMR spectrum of 15

$^{13}C$ NMR spectrum of 15
LC chromatogram of 15
Figure S3. Ligand Density map of the bound inhibitor 9 in Complex with *Mtb* HadAB - Polder omit electron density $F_o$-$F_c$ map for the ligand 9 bound to *Mtb* HadAB. Electron density is displayed as mesh, with a 5σ cutoff. The HadA subunit ribbon is colored yellow while the B subunit ribbon is colored green with the ligand carbons colored cyan.
Figure S4. 3D illustrations of the binding modes of butein (A) and fisetin (B) the HadAB complex - PDB ID: 4RLW and 4RLT respectively. Butein (A) interacts predominantly with the S1 subsite forming π-interactions with A-Y65 and hydrogen bonds to A-Q89 and A-Q86. Hydrogen bonds to A-N126 and A-T138 are present in the S4 subsite. Hydrogen bonds with two water molecules interacting with the catalytic dyad of B-D-36 and B-H41 are observed but no direct interactions with the catalytic hooks of the S2 main chain amides of A-Q86 and B-G59. These interactions are crucial for positioning the substrate for the dehydratase reaction catalysed by the B-D36/B-H41 dyad. (B) Fisetin, a coumarin also interacts predominantly with the S2 and S4 subsites. The coumarin group occupies the S4 cavity, forming hydrogen bonds with 3 water molecules, B-N125 and B-Q68. The dihydroxyphenyl group interacts with the S1 subsite via a π-interactions with A-Y65 and a hydrogen bond with lone water, not engaging with the water network around the catalytic dyad or the catalytic hooks of the A-Q86 and B-G59 main chain amides.
Figure S5. The unliganded structure or the *Mtb*HadBC (HadB – light green, HadC – orange) superimposed onto the crystal structure of *Mtb*HadAB (HadA – yellow, HadB lime green) in complex with 9 (turquoise). The two HadB subunits are shown to be identical while the HadC and HadB subunits are identical in the S2 subsite that interacts with the acyl sulfonamide moiety. The big difference occurs in the S3 subsite with the A-Y65 for C-K65 change. The apo form of the HadBC complex is also unsuitable for ligand docking due to the flexible C-K65 interfering with the ligand binding and a poorly defined region of the S2 subsite around C-I84 (circled in red).
References

(1) Pluskal, T.; Castillo, S.; Villar-Briones, A.; Orešič, M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC Bioinformatics* 2010, 11 (1), 395. DOI: 10.1186/1471-2105-11-395.

(2) Khonde, L. P.; Müller, R.; Boyle, G. A.; Reddy, V.; Nchinda, A. T.; Eyermann, C. J.; Fienberg, S.; Singh, V.; Myrick, A.; Abay, E.; Njoroge, M.; Lawrence, N.; Su, Q.; Myers, T. G.; Boshoff, H. I. M.; Barry, C. E.; Sirgel, F. A.; van Helden, P. D.; Massoudi, L. M.; Robertson, G. T.; Lenaerts, A. J.; Basarab, G. S.; Ghorpade, S. R.; Chibale, K. 1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. *Journal of Medicinal Chemistry* 2021, 64 (17), 12790–12807. DOI: 10.1021/acs.jmedchem.1c00837.